Abstract：Objective：To observe the clinical effect of Xiaoke Powder combined with western medicine for coronary heart disease of phlegm blended with stasis type. Methods：A total of 60 cases of patients with coronary heart disease of phlegm blended with stasis type were selected and randomly divided into the control group and the trial group， with 30 cases in each group. Both groups were given standardized secondary prevention and treatment of coronary heart disease. The trial group was additionally treated with Xiaoke Powder. Both groups were treated for 6 months. Before and after treatment， the scores of the Seattle Angina Questionnaire including scores of physical limitation (PL)， angina stability (AS)， angina frequency (AF)，treatment satisfaction (TS)，and disease perception (DS)，and traditional Chinese medicine (TCM) syndrome scores were counted； fasting blood glucose (FBG)， total cholesterol (TC)， triglyceride (TG)， low- density lipoprotein cholesterol (LDL- C)， high- density lipoprotein cholesterol (HDL- C)， high sensitivity C-reactive protein (hs-CRP)，homocysteine (Hcy)，vascular cell adhesion molecule-1 (VCAM-1)， and microRNA-126 (miRNA-126) were detected. Results：After treatment，levels of Hcy in serum in the two groups were decreased when compared with those before treatment (P＜0.05)，and the level in the trial group was lower than that in the control group (P＜0.05). Scores of PL，AS，AF，TS，and DS in the two groups were increased when compared with those before treatment (P＜0.05)，and the scores of PL， AS，AF，and TS in the trial group were higher than those in the control group (P＜0.05). TCM syndrome scores in the two groups were decreased when compared with those before treatment (P＜0.05)，and the TCM syndrome score in the trial group was lower than that in the control group (P＜0.05). The levels of TG， TC，HDL- C，and LDL- C in the two groups were lower than those before treatment (P＜0.05)，and the four levels in the trial group were lower than those in the control group (P＜0.05). The levels of VCAM-1 in the two groups were lower than those before treatment，and the miR-126 expression was higher than that before treatment，differences being significant (P＜0.05). There was no significant difference being found in the comparison of miR-126 expression between the two groups (P＞0.05). The level of VCAM-1 in the trial group was lower than that in the control group (P＜0.05). Conclusion： Xiaoke Powder based on the standardized treatment scheme for patients with coronary heart disease of phlegm blended with stasis type can effectively relieve clinical symptoms such as chest tightness and chest pain，and improve the quality of life of patients. On the other hand，it also confirms that Xiaoke Powder can further strengthen the role of stabilizing plaque and anti- atherosclerosis by affecting the content of VCAM- 1 and the expression of miR-126.